Healthcare Finance News September 6, 2023
Jeff Lagasse

The QMM program aims to encourage drug manufacturers to implement quality management practices that go beyond current requirements.

Quality issues are still the number one reason for drug shortages, and in an effort to address this, the U.S. Food and Drug Administration is debuting a quality management maturity (QMM) program intended to incentivize drugmakers to invest in quality measures.

The program will be run by the FDA’s Center for Drug Evaluation and Research (CDER), which is developing its QMM Assessment Tool to evaluate how effectively establishments monitor and manage quality and quality systems. The QMM program aims to encourage drug manufacturers to implement quality management practices that go beyond current good manufacturing practice (CGMP) requirements.

In a white paper, the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
The telehealth background of Trump's FDA pick: 6 notes
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Opinion: RFK Jr. and MAHA should champion a Marshall Plan for obesity
Trump picks Johns Hopkins surgeon to head FDA: 10 things to know
Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices

Share This Article